Business Daily Media

The Times Real Estate

.

HKU AIDS Institute & Immuno Cure’s Collaborative Therapeutic HIV Vaccine Research Project secured HK$66.7m TRS funding from Research Grant Council

Research Funding for Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions

HONG KONG SAR - Media OutReach Newswire - 18 July 2024 - Immuno Cure BioTech ("Immuno Cure") is pleased to announce today that a collaborative research entitled "Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions" ("Project") led by Prof.

Zhiwei Chen of The University of Hong Kong ("HKU") on our therapeutic HIV vaccine ("ICVAX") has been awarded HK$66.7 million of funding under the Theme-based Research Scheme ("TRS") of the Research Grants Council ("RGC") for a second 5-year term.

HIV/AIDS are a global health concern, especially significant in Hong Kong. Based on Centre for Health Protection's record, a cumulative total of 12,143 cases of HIV infection and 2,507 cases of AIDS are found in Hong Kong, which have been steadily increasing over the years. The current combination antiretroviral therapy ("cART") target suppressing viral reproduction while this project will further investigate the effect of using our PD-1-enhanced DNA vaccine technologies on immunogenicity.

The Project is led by Professor Zhiwei Chen, Director of the AIDS Institute and Chair Professor of the Department of Microbiology, School of Clinical Medicine, LKS Faculty of Medicine of HKU, and the Principal Scientific Advisor of Immuno Cure. The research will be performed in collaboration with Immuno Cure, Chinese University of Hong Kong Phase 1 Clinical Trial Centre, The Third People's Hospital of Shenzhen, and other hospitals in the Mainland where the collaborative team of researchers will investigate and determine the mechanism of PD-1-based DNA vaccine-mediated 7-year cART-free virologic control in SHIV-infected rhesus monkeys; the impact of PD-1-base DNA vaccine on cART-treated people living with HIV-1 ("PLWH"); and the sustained cART-free HIV-1 control using analytical treatment interruption ("ATI") and combinational immunotherapy.

Immuno Cure will contribute to the manufacturing of ICVAX and the design and management of the clinical trials with our aim to determine the ATI amongst the PLWH of ICVAX Phase 1 Trial; to optimise the immunogenicity of ICVAX by conducting a multi-centre Phase 2 Trial; and to determine the immunotherapeutic efficacy by combining ICVAX with other complementary strategies. This Project will strengthen Hong Kong Research Consortium on HIV/AIDS in collaboration with international experts and scientific advisors, and also reveal mechanisms underlying a promising "Made in Hong Kong" immunotherapy in clinical trials. It will ultimately contribute to the understanding of long-term viral control and potential alternative treatment strategies for HIV-1 without cART treatment in future.

Prof. Zhiwei CHEN, Director of AIDS Institute of HKU and the Principal Scientific Advisor of Immuno Cure, said "Preliminary Phase 1 Trial data demonstrated that the HKU patented PD-1-enhanced DNA vaccine ICVAX has shown convincing safety and immunogenicity profiles in PLWH. Our team members are very grateful that this TRS grant will allow us to expand our translational research to benefit more and more PLWH."

Dr. Xia JIN, CEO of Immuno Cure & Co-PI of the Project, said, "We are excited to be a key member of the collaborative research team led by Prof. Chen, with whom we have many years of close working relationship. This TRS-funded research will enhance our understanding of the mechanisms of the immune protection and enable us to further investigate the potential of ICVAX towards functional cure of HIV/AIDS."

Dr. Percy CHENG, Chairman of Immuno Cure, concluded, "Immuno Cure is delighted to have earned RGC's support and recognition of our ICVAX research which is of strategic importance to Hong Kong's long-term development. This milestone allows us to carry out academic collaborative research with HKU's AIDS Institute and other top ranked universities in Hong Kong and the Mainland for the advancement of our combat against HIV/AIDS. We are also grateful for the involvement of all the global expert advisors organised by Prof. Chen."

Hashtag: #ImmunoCure #HKU #AIDS

The issuer is solely responsible for the content of this announcement.

About Immuno Cure

Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody platforms; with two DNA vaccine candidates currently in clinical trials.

To learn more about Immuno Cure, please visit:

About The University of Hong Kong and AIDS Institute of HKUMed

The University of Hong Kong (HKU), founded in 1911, is the first and oldest institution of higher learning in Hong Kong. HKU has an established worldwide reputation for being a research-led comprehensive university. The AIDS Institute of HKU was established in November 2007 to take HKU in a new strategic direction in fighting this global epidemic and help to make it a leader in the region in AIDS research, education and prevention. Scientists at the AIDS Institute are fully committed to conducting basic and applied research that facilitates the understanding of AIDS pathogenesis and the development of effective AIDS vaccines. Furtherance to the Hong Kong Theme-based Research Scheme entitled "Potentiating Host Immunity for HIV-1 Functional Cure", the institute is currently leading the second 5-year term research entitled "Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions".

To learn more about HKU and AIDS Institute of HKU, please visit and

About Research Grant Council and Theme-based Research Scheme

To learn more about RGC, please visit:

To learn more about TRS, please visit:

News from Asia

SonicWall Redefines Cybersecurity, Sets New Standard with Next Generation Network Security Solutions Built for MSPs

Delivering peace of mind with layered security, co-managed services and a unified management platform, SonicWall is helping partners grow services profitably through its continued innovation levera...

BNM’s Policy Rate Call Looms: Octa Broker Highlights Inflation, Exchange Rate and Trade Challenges

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 6 May 2025 - This Thursday, Bank Negara Malaysia (BNM) will announce its policy rate decision. While most analysts expect no change, Octa Broker ...

TDCX retains rank as the top Southeast Asian outsourced CX provider

Among top 17 globally in OA500 Index that evaluates BPO firms worldwide SINGAPORE - Media OutReach Newswire - 7 May 2025 - TDCX, a leading global business process outsourcing (BPO) company for te...

NIA Eyes Green Tech Unicorns Within Three Years, Four Thai Startups Set to Showcase at ‘Web Summit Qatar 2025’ as Global Green Innovation Market Forecasts 25% Annual Growth Over the Next Decade

BANGKOK, THAILAND - Media OutReach Newswire - 7 May 2025 - The Ministry of Higher Education, Science, Research and Innovation (MHESI), through the National Innovation Agency (Public Organization)...

Trend Micro Delivers AI-Powered Threat Detection with AWS Infrastructure Support and NVIDIA Integration

Proactive security with AI-powered model built for modern enterprise workloads HONG KONG SAR - Media OutReach Newswire - 7 May 2025 - Trend Micro Incorporated (TYO: 4704; TSE: 4704), a global cyb...

Bee Choo Origin Strengthens CSR Efforts with Electric Van Donation to NKF

SINGAPORE - Media OutReach Newswire - 7 May 2025 – Bee Choo Origin, Singapore’s leading herbal hair care brand that specialises in hair fall treatment and oily scalp treatment, has reaffirmed it...

SMART launches new research group WISDOM to pioneer technologies that will help machines "see" like humans

Multi-million-dollar, three-and-a-half-year programme to advance Singapore’s optoelectronics and photonics capabilities and semiconductor industry, which generated over S$133 billion in 202...

Vingroup and the Rise of the ESG Ecosystem

Vingroup is positioning itself to lead Vietnam's ESG push, using its broad business network to drive sustainable growth at home and abroad, while eyeing partnerships in the Middle East's expanding ...

DFI Retail Group and Dingdong Announce Strategic Partnership With first-year sales target of HKD100 million

HONG KONG SAR - Media OutReach Newswire - 7 May 2025 - DFI Retail Group (DFI or the Group), and Dingdong (Cayman) Limited (Dingdong or DDL), a leading fresh food e-commerce platform in the mainlan...

Blue Cross Surpasses Market Average with Over 20% Growth in 2024

HONG KONG SAR - Media OutReach Newswire - 7 May 2025 - Blue Cross (Asia-Pacific) Insurance Limited ("Blue Cross") reported outstanding performance in the 2024 provisional statistics for Hong Kong ...

UNSW startup accelerator offers $200K to the next generation of Australian deeptech unicorns

UNSW Founders, Australia’s most recommended startup accelerator, has partnered with fund manager Luminary Partners to invest $200,000 each into 18...

The Future Is Now: AI Modernization Is Reshaping How Business Gets Done

The present business environment imposes stronger requirements on Australian organizations to match the fast-paced digital-first economy requireme...

Businesses losing an average of $493k from data integrity flaws

Managing data responsibly and effectively for the AI age can give organisations a strong competitive advantage, but many are failing to harness th...

AI shopping disruptor Zyft raises $7.5M to lead the next gen of retail tech

Zyft appoints new CEO, Richard Stevens, to lead the latest Waller Group success story, valued at $30 million SYDNEY, 28 April 2025: Zyft, the lea...

Little known law offers savvy Kiwis the opportunity to supercharge their retirement savings

A little-known legal amendment is being leveraged by savvy New Zealanders and expat Brits to supercharge their retirement savings. Not many peop...

Cutting edge AI technology designed for doctors to reduce patient wait times launched in NZ

New Zealand specialist doctors now have access to Artificial Intelligence technology to help reduce patient wait times and experts say it could be...

Sell by LayBy